Nurix Therapeutics Inc (NAS:NRIX)
$ 15.9 0.95 (6.35%) Market Cap: 970.97 Mil Enterprise Value: 698.12 Mil PE Ratio: 0 PB Ratio: 4.35 GF Score: 67/100

Nurix Therapeutics Inc Development Under Stress - Finding New Ubiquitylation Enzymes for Therapeutic Benefit Transcript

Oct 13, 2020 / NTS GMT
Release Date Price: $25.57 (+1.23%)
Jennifer Doudna
Intellia Therapeutics, Inc. - Co-Founder

Okay, we're zooming past 50 people. So [Micha], maybe we'll go ahead and get started.

Michael RapÃ;Nurix Therapeutics
Inc. - Founder and member of Scientific Advisory Board

©, -

Let's go, Jennifer.

Jennifer Doudna
Intellia Therapeutics, Inc. - Co-Founder

Okay, great. Well, hi, everybody. It's an incredible pleasure to be able to introduce my Berkeley colleague, Michael Rapé to you today. And I wanted to tell you a little bit about Michael's background. So he's been a member of the Berkeley faculty since 2006. He's currently the Peter Hirth Chair of Cancer Biology and an investigator of the Howard Hughes Medical Institute.

And before coming to Berkeley, he was a graduate student at the Max Planck Institute in Martinsried followed by working as a postdoctoral scholar with Marc Kirschner at Harvard Medical School. And he's had a longstanding interest in quality control, especially quality control of proteins and understanding cell-fate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot